The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas.
The majority of patients with aggressive non-Hodgkin's lymphomas (NHLs) still die of their disease. Although clinical prognostic factors can be used to characterize a patient's risk profile, these clinical features are likely to be surrogate variables for the intrinsic cellular and molecular heterogeneity of the aggressive NHLs. The purpose of this review is to identify newly described cellular and molecular features of aggressive NHLs that may be of prognostic value.
Howard
O M
OM
Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Shipp
M A
MA
D015815:Cell Adhesion Molecules / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D016228:Endothelial Growth Factors / Q000378:metabolism; D016147:Genes, Tumor Suppressor / Q000235:genetics; D018740:Genetic Heterogeneity; D006801:Humans; D008222:Lymphokines / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000737:chemistry* / Q000145:classification / Q000235:genetics*; D008666:Metalloendopeptidases / Q000378:metabolism; D009154:Mutation; D011519:Proto-Oncogenes / Q000235:genetics; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism; D014178:Translocation, Genetic; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D015815:Cell Adhesion Molecules; D016207:Cytokines; D016228:Endothelial Growth Factors; D008222:Lymphokines; D019714:Tissue Inhibitor of Metalloproteinases; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D008666:Metalloendopeptidases